StaGen

StaGen is a South Korean biotechnology company focused on the development of first-in-class anti-cancer therapeutics targeting cancer stem cells (CSCs) and metastasis. The company's primary approach involves inhibiting the STAT3 signaling pathway, which plays a critical role in tumor recurrence and resistance to conventional therapies. Its lead program, STG-001, is a small molecule inhibitor currently being evaluated in clinical trials for patients with advanced solid tumors. StaGen aims to address the high unmet medical need in oncology by preventing cancer spread and improving long-term survival outcomes. The company leverages proprietary screening technologies to identify compounds that specifically disrupt the survival mechanisms of resilient cancer cells.